Investing.comDoubao · 实盘不做把握 6/10不做原因:无增量信息
北京时间·🕒 发布 19:36:41·⟳ 抓取 19:37:08 +27s·⚡ 决策 10-12 19:39:28 +2m20s·15.1 天前
Palvella 在 Fall Clinical 2026 展示三张 QTORIN 雷帕霉素凝胶海报，均为已知 SELVA 数据的二次呈现
本次是学术会议海报展示：核心 SELVA 95%主要终点数据 2026年2月已发、5月ISSVA已展示，NDA 8月已完成滚动提交；新增仅为患者访谈、PK安全性支持数据和 DSAP 流行病学（服务于另一在研药 pitavastatin），均不改变估值锚。消息源为 Investing.com 的 AI 生成改写稿，且 PVLA 上一交易日(10/9)已上涨5.66%，有预期抢跑，短线风险收益不对称；数据本身偏正面，不构成做空催化。
📄 原文Investing.com↗ 原文
Palvella presents data on rapamycin gel, DSAP patient analysis
By Investing.com Advertisement Advertisement Palvella presents data on rapamycin gel, DSAP patient analysis Company New…
不做 Palvella Therapeutics（PVLA.US）
无增量事实：SELVA 95%主要终点数据2026年2月已公布、5月已在ISSVA展示，NDA 8月已滚动提交，本次仅为患者访谈/PK安全性/DSAP流行病学等二次支持数据，无新关键读数或监管节点；上一交易日已抢跑+5.66%，会议海报卖事实/见光死风险高，追多无正edge。数据偏正面且NDA催化在途，不构成做空理由，故多空均不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
QTORIN 海报是对已成功 3 期 SELVA 和已提交 NDA 的二次确认，无新关键试验读出或监管节点，属学术推广性数据；PVLA 上周五已提前上涨5.66%，会议海报见光死/卖事实风险高，多空均无edge，回避。
消息传播链
- 公司新闻稿首发三张 Fall Clinical 2026 海报，内容为 SELVA、PK 子研究与 DSAP 理赔分析，无新监管节点。
- 信号源为公司新闻稿的 AI 改写转载，非独立报道，增量信息为零。市场反应:上一交易日 10/9 PVLA 收涨 5.66% 至 138.77 美元，疑似会议前抢跑；本消息发布时美股盘前未开盘。
关键理由
- SELVA 阳性顶线(2026年2月)与 ISSVA 展示(2026年5月)均为旧信息，本次海报未提供新的pivotal读数或NDA/PDUFA监管增量。
- PVLA 为约20亿美元市值、尚未盈利的临床期公司，会议前一交易日已放量上涨5.66%，低增量海报难以继续重定价。
主要风险
- NDA 若近期获 FDA 受理或给出 PDUFA 日期，可能成为独立新催化而令回避踏空（但不属本事件）。
- DSAP 流行病学数据为 Q4 启动的 pitavastatin 2期铺垫，市场若据此上调第二成长曲线预期，股价仍可能被情绪推高。
反向证据
- 做多前查反向 · 来源 web · 影响 weakens
未检索到本次海报后的新增利空或监管挫折；但反证检索同时确认核心数据均为旧闻，缺乏新增利好，长线催化仍待FDA受理/PDUFA。
检索:Palvella PVLA NDA delay FDA setback safety concern 2026 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足叠加事件本身无增量，支持以回避而非追多处理；亦不支持做空。
方向:无足够同市场、同相位（学术会议海报二次展示已读出数据）的对齐先例可供定量校准。
涨幅量级:未取得高相似对齐先例，不用任何涨幅数字设定止盈止损。
形态:生物医药'已知顶线数据的会议海报'普遍偏卖事实，但本次未用历史面板定量验证。
工具执行结果 · 成功 4 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 12 ms
{"result": "search_processed_events:agent query=`palvella pvla dsap claims analysis nda rapamycin | palvella qtorin rapamycin gel selva phase 3 poster fall clinical dermatology 2026 | palvella therapeutics lymphatic malformation `；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agen - stock_quote 成功 stock_tools HTTP · 8,475 ms
{ - web_search 成功 doubao_search · 2,883 ms
豆包搜索结果（原始查询:Palvella SELVA Phase 3 QTORIN rapamycin topline results announcement lymphatic malformation；API SearchType:web） - web_search 成功 doubao_search · 1,808 ms
豆包搜索结果（原始查询:Palvella PVLA Fall Clinical Dermatology conference October 2026 posters QTORIN news；API SearchType:web）
原文全文
展开原文 · 7,348 字
Palvella presents data on rapamycin gel, DSAP patient analysis By Investing.com
Advertisement
Advertisement
Palvella presents data on rapamycin gel, DSAP patient analysis
Company News
Published
Oct 12, 2026, 07:36 AM
Palvella presents data on rapamycin gel, DSAP patient analysis
View all comments (0)
0
Palvella presents data on rapamycin gel, DSAP patient analysis
View all comments (0)
0
© Reuters
In this article:
PVLA
+
5.66%
WAYNE, Pa. -
Palvella Therapeutics
Inc. (
NASDAQ:PVLA
) presented three posters at the 26th Annual Fall Clinical Dermatology Conference on Monday, according to a press release statement.
The presentations included findings from the Phase 3 SELVA study of QTORIN rapamycin gel for microcystic lymphatic malformations, a pharmacokinetic substudy, and a real-world claims analysis of disseminated superficial actinic porokeratosis patients.
In the SELVA study, interviews with patients, caregivers, and clinicians at Week 24 showed all exit-interview participants reported improvement in at least one symptom, most commonly bleeding or leaking and color. Among participants who completed the 24-week period, 95% demonstrated improvement on the study’s primary endpoint, with 86% rated as Much Improved or Very Much Improved. Additionally, 98% of participants elected to continue treatment in an extension period.
The pharmacokinetic substudy involving 24 participants showed mean systemic rapamycin exposure with QTORIN was at least 40-fold lower than reported exposure with oral sirolimus. Systemic concentrations remained low and stable over 24 hours across different age groups, treated lesion areas, and disease severities.
A separate real-world claims analysis of U.S. paid claims data from Komodo Health identified an estimated 154,986 patients diagnosed with DSAP during 2018-2025. The methodology required at least two occurrences of ICD-10 diagnosis code L56.5 and adjustments for age-specific population capture rates.
Palvella completed the rolling submission of its New Drug Application to the FDA for QTORIN rapamycin in August 2026. The company plans to commence a Phase 2 trial of QTORIN pitavastatin for DSAP treatment in the fourth quarter of 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Palvella presents data on rapamycin gel, DSAP patient analysis
View all comments (0)
0
Latest comments
Post
Comment Guidelines
Trade With A Regulated Broker
Indices
Commodities
Bonds
Stocks
US 30
51,709.60
+54.4
+0.11%
US 500
7,816.20
+4.7
+0.06%
Dow Jones
51,654.95
+423.31
+0.83%
S&P 500
7,811.54
+46.18
+0.59%
Nasdaq
27,366.17
+172.83
+0.64%
S&P 500 VIX
15.47
+0.63
+4.25%
Dollar Index
102.22
+0.198
+0.19%
Crude Oil WTI Futures
93.02
+1.17
+1.27%
Brent Oil Futures
106.09
+1.37
+1.31%
Natural Gas Futures
3.122
-0.098
-3.04%
Gold Futures
4,195.51
-20.79
-0.49%
Silver Futures
60.915
-0.133
-0.22%
Copper Futures
6.773
+0.0810
+1.21%
US Soybeans Futures
1,283.50
-7.50
-0.58%
U.S. 10Y
5.256
+0.012
+0.23%
U.S. 30Y
5.599
-0.008
-0.14%
U.S. 5Y
5.021
+0.030
+0.60%
U.S. 3M
4.159
+0.008
+0.19%
US 10Y T-Note Futures
104.52
-0.08
-0.07%
Euro Bund Futures
121.07
-0.02
-0.01%
10-2 Yield Spread
31.32
+4.15
+15.27%
AAPL
336.64
-3.78
-1.11%
NVDA
229.28
-1.20
-0.52%
GOOGL
351.66
+3.37
+0.97%
TSLA
382.70
+7.70
+2.05%
AMZN
262.43
+8.37
+3.29%
NFLX
70.30
-1.27
-1.77%
META
718.67
-2.22
-0.31%
Advertisement
Most Popular Articles
News
Analysis
Goldman names 3 names to benefit as high-performance NAND tackles AI’s memory wall
By Investing.co
...
Oct 12, 2026
Oil falls, CPI and bank earnings in focus - what’s moving markets
By Investing.co
...
Oct 12, 2026
What the sell off in bonds means for monetary policy
By Investing.co
...
Oct 11, 2026
8 emerging markets to consider in 2027: HSBC
By Investing.co
...
Oct 11, 2026
Broadcom CEO says many AI investors are gamblers
By Investing.co
...
Oct 12, 2026
Sequence of Return Risk: The Math That Breaks Retirements
By Lance Robert
...
Oct 10, 2026
Beyond Chips: The 3 Layers of the AI Value Chain
By Ivana Delevs
...
Oct 10, 2026
OpenAI’s $20B Revenue Gap: Warning Signs for US Stocks?
By Lee Yang
Oct 09, 2026
Wall Street’s Busy Week: Bank Results, CPI and Retail Sales in Focus
By Ali Merchant
Oct 12, 2026
Treasury Auctions Explained: Why Bond Auctions Matter Even If You Dont Trade Bonds
By Matthew Well
...
Oct 10, 2026
More News
Market Movers
Most Active
Gainers %
Losers %
Name
Last
Chg. %
Vol.
MU
1,029.00
-0.66%
19.92M
NVDA
229.28
-0.52%
84.65M
SPCX
162.57
+1.25%
93.04M
TSLA
382.70
+2.05%
38.95M
AAPL
336.64
-1.11%
37.88M
MSFT
535.07
+2.38%
18.50M
AMZN
262.43
+3.29%
34.77M
Name
Last
Chg. %
Vol.
CCI
79.64
+15.60%
14.39M
MRNA
225.00
+14.21%
28.95M
HUM
431.87
+11.56%
4.99M
AMT
182.24
+9.30%
8.51M
SBAC
182.49
+7.34%
2.36M
DDOG
293.26
+7.11%
3.71M
AKAM
106.95
+6.00%
5.80M
Name
Last
Chg. %
Vol.
TMUS
148.58
-13.27%
19.03M
T
22.18
-10.82%
150.53M
VZ
41.65
-10.14%
95.17M
HPQ
30.20
-6.91%
16.70M
FMC
8.35
-6.39%
5.19M
CHTR
103.38
-5.74%
5.11M
FICO
667.58
-5.63%
1.09M
Advertisement
Trending Stocks
Name
Last
Chg. %
Vol.
MU
1,029.00
-0.66%
19.92M
NVDA
229.28
-0.52%
84.65M
SPCX
162.57
+1.25%
93.04M
PLTR
209.05
+5.17%
37.62M
IREN
35.190
-1.46%
38.53M
Show more
Advertisement
ProPicks AI
AI-powered
stock picks
with a proven track record to
beat the S&P 500
.
Tech Titans
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Top Value Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best of Buffett
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Energy Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Financial Fortresses
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Quality Compounders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Small-Cap Sprinters
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Healthcare Heroes
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Beat the S&P 500
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Dominate the Dow
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mid-Cap Movers
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mexican Stock Exchange Leaders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best Brazilian Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Italian Market Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Alpha Germany Select
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Comments
Post
Comment Guidelines
Tools
Calendars
Economic Calendar
Earnings Calendar
Holiday Calendar
US Economy
Fed Rate Monitor Tool
US Treasury Yield Curve
More Tools
Stock Screener
Currency Converter
Markets
Ask WarrenAI
Stocks Picked by AI
Watchlist
Alerts
Top Brokers
Breaking News
Tools
Install Our App
Scan QR code to install app
Follow us
Advertisement
Advertisement
Palvella presents data on rapamycin gel, DSAP patient analysis
Company News
Published
Oct 12, 2026, 07:36 AM
Palvella presents data on rapamycin gel, DSAP patient analysis
View all comments (0)
0
Palvella presents data on rapamycin gel, DSAP patient analysis
View all comments (0)
0
© Reuters
In this article:
PVLA
+
5.66%
WAYNE, Pa. -
Palvella Therapeutics
Inc. (
NASDAQ:PVLA
) presented three posters at the 26th Annual Fall Clinical Dermatology Conference on Monday, according to a press release statement.
The presentations included findings from the Phase 3 SELVA study of QTORIN rapamycin gel for microcystic lymphatic malformations, a pharmacokinetic substudy, and a real-world claims analysis of disseminated superficial actinic porokeratosis patients.
In the SELVA study, interviews with patients, caregivers, and clinicians at Week 24 showed all exit-interview participants reported improvement in at least one symptom, most commonly bleeding or leaking and color. Among participants who completed the 24-week period, 95% demonstrated improvement on the study’s primary endpoint, with 86% rated as Much Improved or Very Much Improved. Additionally, 98% of participants elected to continue treatment in an extension period.
The pharmacokinetic substudy involving 24 participants showed mean systemic rapamycin exposure with QTORIN was at least 40-fold lower than reported exposure with oral sirolimus. Systemic concentrations remained low and stable over 24 hours across different age groups, treated lesion areas, and disease severities.
A separate real-world claims analysis of U.S. paid claims data from Komodo Health identified an estimated 154,986 patients diagnosed with DSAP during 2018-2025. The methodology required at least two occurrences of ICD-10 diagnosis code L56.5 and adjustments for age-specific population capture rates.
Palvella completed the rolling submission of its New Drug Application to the FDA for QTORIN rapamycin in August 2026. The company plans to commence a Phase 2 trial of QTORIN pitavastatin for DSAP treatment in the fourth quarter of 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Palvella presents data on rapamycin gel, DSAP patient analysis
View all comments (0)
0
Latest comments
Post
Comment Guidelines
Trade With A Regulated Broker
Indices
Commodities
Bonds
Stocks
US 30
51,709.60
+54.4
+0.11%
US 500
7,816.20
+4.7
+0.06%
Dow Jones
51,654.95
+423.31
+0.83%
S&P 500
7,811.54
+46.18
+0.59%
Nasdaq
27,366.17
+172.83
+0.64%
S&P 500 VIX
15.47
+0.63
+4.25%
Dollar Index
102.22
+0.198
+0.19%
Crude Oil WTI Futures
93.02
+1.17
+1.27%
Brent Oil Futures
106.09
+1.37
+1.31%
Natural Gas Futures
3.122
-0.098
-3.04%
Gold Futures
4,195.51
-20.79
-0.49%
Silver Futures
60.915
-0.133
-0.22%
Copper Futures
6.773
+0.0810
+1.21%
US Soybeans Futures
1,283.50
-7.50
-0.58%
U.S. 10Y
5.256
+0.012
+0.23%
U.S. 30Y
5.599
-0.008
-0.14%
U.S. 5Y
5.021
+0.030
+0.60%
U.S. 3M
4.159
+0.008
+0.19%
US 10Y T-Note Futures
104.52
-0.08
-0.07%
Euro Bund Futures
121.07
-0.02
-0.01%
10-2 Yield Spread
31.32
+4.15
+15.27%
AAPL
336.64
-3.78
-1.11%
NVDA
229.28
-1.20
-0.52%
GOOGL
351.66
+3.37
+0.97%
TSLA
382.70
+7.70
+2.05%
AMZN
262.43
+8.37
+3.29%
NFLX
70.30
-1.27
-1.77%
META
718.67
-2.22
-0.31%
Advertisement
Most Popular Articles
News
Analysis
Goldman names 3 names to benefit as high-performance NAND tackles AI’s memory wall
By Investing.co
...
Oct 12, 2026
Oil falls, CPI and bank earnings in focus - what’s moving markets
By Investing.co
...
Oct 12, 2026
What the sell off in bonds means for monetary policy
By Investing.co
...
Oct 11, 2026
8 emerging markets to consider in 2027: HSBC
By Investing.co
...
Oct 11, 2026
Broadcom CEO says many AI investors are gamblers
By Investing.co
...
Oct 12, 2026
Sequence of Return Risk: The Math That Breaks Retirements
By Lance Robert
...
Oct 10, 2026
Beyond Chips: The 3 Layers of the AI Value Chain
By Ivana Delevs
...
Oct 10, 2026
OpenAI’s $20B Revenue Gap: Warning Signs for US Stocks?
By Lee Yang
Oct 09, 2026
Wall Street’s Busy Week: Bank Results, CPI and Retail Sales in Focus
By Ali Merchant
Oct 12, 2026
Treasury Auctions Explained: Why Bond Auctions Matter Even If You Dont Trade Bonds
By Matthew Well
...
Oct 10, 2026
More News
Market Movers
Most Active
Gainers %
Losers %
Name
Last
Chg. %
Vol.
MU
1,029.00
-0.66%
19.92M
NVDA
229.28
-0.52%
84.65M
SPCX
162.57
+1.25%
93.04M
TSLA
382.70
+2.05%
38.95M
AAPL
336.64
-1.11%
37.88M
MSFT
535.07
+2.38%
18.50M
AMZN
262.43
+3.29%
34.77M
Name
Last
Chg. %
Vol.
CCI
79.64
+15.60%
14.39M
MRNA
225.00
+14.21%
28.95M
HUM
431.87
+11.56%
4.99M
AMT
182.24
+9.30%
8.51M
SBAC
182.49
+7.34%
2.36M
DDOG
293.26
+7.11%
3.71M
AKAM
106.95
+6.00%
5.80M
Name
Last
Chg. %
Vol.
TMUS
148.58
-13.27%
19.03M
T
22.18
-10.82%
150.53M
VZ
41.65
-10.14%
95.17M
HPQ
30.20
-6.91%
16.70M
FMC
8.35
-6.39%
5.19M
CHTR
103.38
-5.74%
5.11M
FICO
667.58
-5.63%
1.09M
Advertisement
Trending Stocks
Name
Last
Chg. %
Vol.
MU
1,029.00
-0.66%
19.92M
NVDA
229.28
-0.52%
84.65M
SPCX
162.57
+1.25%
93.04M
PLTR
209.05
+5.17%
37.62M
IREN
35.190
-1.46%
38.53M
Show more
Advertisement
ProPicks AI
AI-powered
stock picks
with a proven track record to
beat the S&P 500
.
Tech Titans
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Top Value Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best of Buffett
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Energy Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Financial Fortresses
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Quality Compounders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Small-Cap Sprinters
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Healthcare Heroes
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Beat the S&P 500
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Dominate the Dow
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mid-Cap Movers
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mexican Stock Exchange Leaders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best Brazilian Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Italian Market Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Alpha Germany Select
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Comments
Post
Comment Guidelines
Tools
Calendars
Economic Calendar
Earnings Calendar
Holiday Calendar
US Economy
Fed Rate Monitor Tool
US Treasury Yield Curve
More Tools
Stock Screener
Currency Converter
Markets
Ask WarrenAI
Stocks Picked by AI
Watchlist
Alerts
Top Brokers
Breaking News
Tools
Install Our App
Scan QR code to install app
Follow us
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
8d61ab9ce1· 2026-10-12 19:39 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前